Welcome to our dedicated page for NEWCELX news (Ticker: NLSPW), a resource for investors and traders seeking the latest updates and insights on NEWCELX stock.
The NLSPW news page aggregates announcements and disclosures related to the warrants of NLS Pharmaceutics Ltd., a Swiss-based clinical-stage biopharmaceutical company whose common shares trade on Nasdaq under the symbol NLSP. Because NLSPW is tied to the company’s capital structure, news about these warrants is closely connected to NLS Pharmaceutics’ corporate transactions, financing activities, and strategic developments.
Readers can expect NLSPW-related coverage to reflect key milestones in NLS Pharmaceutics’ evolution, including its proposed and approved merger with Kadimastem Ltd., the planned rebranding and listing of the combined company as NewCelX Ltd. under the ticker NCEL, and the company’s statements that its currently traded warrants will not be listed for trading post-merger. News items often discuss how equity financings, warrant exchanges, and reverse share splits interact with the company’s broader strategic plans.
Beyond capital markets events, NLSPW-linked news will also reference NLS Pharmaceutics’ scientific and clinical updates, since these can influence the context in which the warrants were originally issued. Recent press releases highlight preclinical data for Mazindol in fentanyl use disorder, new findings for the AEX-2 and AEX-41 dual orexin receptor agonists, and expansion of the DOXA platform through collaboration with Aexon Labs. Other announcements describe how the merger with Kadimastem brings together small-molecule CNS programs with cell therapy platforms such as AstroRx® for ALS and IsletRx for diabetes.
By following this page, investors can review how NLSPW fits into the company’s historical financing structure, track corporate actions that may affect the warrants, and read the underlying scientific and strategic news that NLS Pharmaceutics and its merger partner disclose through press releases and SEC-linked communications.
NLS Pharmaceutics (NASDAQ:NLSP) and Aexon Labs expanded the DOXA platform with the AEX-6xx small-molecule series targeting arousal stability, cognition, and neuroprotection. Lead compound AEX-635 also modulates MRP1, which may aid neuroprotection and CNS bioavailability. The companies reported robust preclinical efficacy (up to 80% cataplexy reduction; >70% wakefulness increase) and plan IND-enabling studies. Financing includes ~$7M equity raised and a $25M equity line of credit, supporting operations for at least 12 months. Patents WO2024141660 and WO2024115797 are in national phases. NewCelX formation follows merger completion.
NLS Pharmaceutics (NASDAQ: NLSP / NLSPW) announced a 1-for-10 reverse share split effective in Switzerland on October 30, 2025, with Nasdaq reflecting the split at market open on October 31, 2025. Following the anticipated merger with Kadimastem, the company will change its name and trade under the new symbol NCEL. The new post‑merger CUSIP is H5835A109.
The amended capital structure lists total share capital of CHF 282,908.80, a capital band allowing issuance up to 2,859,412 common shares, conditional capital provisions, and specific outstanding share counts and warrant figures after the transactions.
NLS Pharmaceutics (NASDAQ: NLSP / NLSPW) and Kadimastem (TASE: KDST) announced that all material conditions precedent for their merger have been satisfied or waived, and the merger closing is set for October 30, 2025. Nasdaq approved listing of the combined company's common shares.
The combined company will be named NewCelX Ltd. and listed on the Nasdaq Capital Market under the ticker NCEL beginning October 31, 2025. Kadimastem trading on TASE will be suspended and its final delisting is scheduled for October 31, 2025.
The final exchange ratio is 7.06 NLS common shares per Kadimastem share, which after a 1-for-10 reverse split of NLS shares becomes 0.706 NLS common shares per Kadimastem share. NewCelX shares are expected to be deposited to Kadimastem shareholders' accounts by the end of day November 3, 2025, with trading availability expected November 4, 2025 or soon thereafter.
NLS Pharmaceutics (Nasdaq: NLSP) and Kadimastem announced an MOU between Kadimastem and TargetGene to jointly develop next-generation gene-edited cell therapies, combining Kadimastem's AstroRx and IsletRx platforms with TargetGene's DNA-guided gene-editing technology.
The collaboration will operate under the combined company NewCelX upon completion of the anticipated merger between NLS and Kadimastem. The MOU frames joint R&D, technology exchange, and potential future licensing to enhance therapeutic performance, stability, and safety with a goal of scalable, curative cell-based treatments.
NLS Pharmaceutics (Nasdaq: NLSP / NLSPW) and Kadimastem (TASE: KDST) received Nasdaq approval for the combined company to list as NewCelX (NCEL) following the closing of their merger, expected on October 30, 2025, with trading under the new name to begin October 31, 2025, subject to customary closing conditions.
The approved exchange ratio yields Kadimastem shareholders ~84.4% ownership and NLS shareholders ~15.6% of the combined company; post-reverse split, each Kadimastem share equals ~0.62 NLS shares. Kadimastem ordinary shares are expected to be delisted from TASE around the closing. Warrant trading will not continue post-merger.
NewCelX will continue clinical programs: AstroRx Phase 2a for ALS and IsletRx pre-IND work toward a Phase 1 diabetes trial; technology transfer and GMP manufacturing setup with Pluri completed.
NLS Pharmaceutics (NASDAQ: NLSP) shareholders have approved the merger with Kadimastem (TASE: KDST) at an Extraordinary General Meeting on September 29, 2025. The combined company will be renamed NewCelX Ltd. and trade on Nasdaq under the ticker "NCEL".
Under the approved terms, Kadimastem shareholders will own 84.4% of the combined company, while NLS shareholders will retain 15.6%. The merger unites Kadimastem's cell therapy programs, including a Phase 2a ALS study of AstroRx® and IsletRx diabetes program, with NLS's CNS small-molecule expertise. Ronen Twito will serve as Executive Chairman & CEO, while Prof. Michel Revel, Kadimastem's founder and developer of the successful MS drug Rebif®, will become Chief Scientific Officer.
NLS Pharmaceutics (NASDAQ:NLSP) and Kadimastem (TASE:KDST) announced the SEC's approval of their Form F-4 registration statement for their planned merger. The combined entity will be named NewCelX Ltd. and trade on Nasdaq as "NCEL".
The merger will unite Kadimastem's cell therapy platforms with NLS's small-molecule expertise. Key programs include Kadimastem's AstroRx®, preparing for Phase 2a trials in ALS, and IsletRx, a stem cell-derived therapy for insulin-dependent diabetes developed with iTolerance. The extraordinary general meeting is scheduled for September 29, 2025.
NLS Pharmaceutics (NLSP) has announced positive results from Study KO-943, evaluating Mazindol's effectiveness in reducing fentanyl-induced reward in mice. The preclinical study demonstrated that Mazindol at 0.5 mg/kg significantly reduced fentanyl-induced conditioned place preference (CPP), bringing behavior close to baseline.
The study utilized four test groups: vehicle control, fentanyl-only, and two fentanyl with Mazindol co-treatment groups. Key findings showed that fentanyl increased place preference (p ≤ 0.05 vs. vehicle), while Mazindol demonstrated a dose-dependent effect in reducing this preference.
Mazindol's mechanism of action includes:
- Partial mu-opioid receptor modulation
- 5-HT1A receptor interaction
- OX2R activity
NLS Pharmaceutics (NASDAQ:NLSP) has secured a $2 million equity financing through preferred shares at $1.65 per share, with potential for an additional $1 million subject to shareholder approval. The company also signed a $25 million committed equity facility agreement.
The funding will support NLS's planned merger with Kadimastem, a clinical-stage cell therapy company focusing on neurodegenerative diseases and diabetes. The merged entity plans to conduct a Phase IIa multi-site clinical trial for AstroRx® in Amyotrophic Lateral Sclerosis (ALS) and a Phase I trial for IsletRx in type 1 diabetes patients post-merger.
The financing, closed on March 28, 2025, was secured at a 10% premium to the market share price. The securities were issued through a private placement under Section 4(a)(2) of the Securities Act and Regulation D. The merger remains subject to regulatory and shareholder approvals.
NLS Pharmaceutics (NLSP) has announced new preclinical findings for AEX-2, their non-sulfonamide dual orexin receptor agonist (DOXA). The research demonstrates promising results in treating narcolepsy and related neurological disorders.
Key findings from preclinical studies show that AEX-2 (20 mg/kg, IP) significantly enhanced wakefulness while maintaining stable wake architecture, preserved REM sleep patterns, and effectively reduced cataplexy episodes in narcolepsy type 1.
The company is expanding its therapeutic potential beyond sleep disorders, with AEX-2 and AEX-41 showing promise in treating neuroinflammation, ALS, Parkinson's disease, and diabetes-associated neurological disorders through Sigma-1 receptor modulation. NLS plans to advance both compounds into IND-enabling studies in 2025, targeting first-in-human clinical trials by 2026.